Company profile
Lexeo Therapeutics, Inc.
NASDAQ:LXEOBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06109181 | phase1_2 | active_not_recruiting | 2024-02-29 | 2026-12-01 | Lexeo Therapeutics | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant |
| NCT03634007 | phase1_2 | completed | 2019-11-06 | 2024-11-07 | Lexeo Therapeutics | Gene Therapy for APOE4 Homozygote of Alzheimer's Disease |
| NCT05445323 | phase1_2 | active_not_recruiting | 2022-08-24 | 2029-09-01 | Lexeo Therapeutics | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia |
| NCT05400330 | phase1 | active_not_recruiting | 2023-05-08 | 2028-11-01 | Lexeo Therapeutics | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease |
| NCT07721025 | phase2 | recruiting | 2026-06-25 | 2032-06-01 | Lexeo Therapeutics | Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy |
FDA applications (0)
No records yet.